25 years of experience in R&D and
industrial use of 3D human tissue models
What do we offer ?
In collaboration with expert centres in 3D human tissue model research and development (and testing services), we offer life-sciences companies:
Ready-to-use methods for compound screening in a variety of validated 3D tissue models of healthy and disease states, including :
- Inflammatory skin diseases
- Oncology
- Infection diseases
- Cardiovascular models
- Neurodegeneration (minibrains)
- Respiratory diseases
- Intestinal diseases
- Blood-Brain Barrier (BBB) model
Research collaborations for the development of ‘on-demand’ 3D tissue models and assays for particular disease states, both human and animal cell based, with a specific focus to highly advanced vascularised tissue models (in house technology).
Examples of R&D and testing services
https://diabetesfrees.com/diabetic-diet-guidelines-for-healthy-eating/ Pharmacology and toxicology on 3D tissue models of healthy and disease states
using state-of the art methods including:
- Tissue morphology (both light and electron microscopy
- Impedance spectroscopy
- Transport assays
- Gene analysis
- Immunohisto and cytochemistry
- Bioavailability
- Cytokine analysis and quantification
- In vitro/in vivo validation
http://baskidesen.com/1267-ph19014-ivermectin-12-mg-tablet-cost.html Recent collaboration agreements:
- Development and validation of an Epidermolysis Bullosa human skin model for compound screening
- Use of organoid minibrain tissues for efficacy screening of Parkinson’s and Alzheimer disease drugs
- Wound-healing efficacy screening on a reconstructed psoriatic disease skin model
- Anti-inflammatory intestinal model for barrier transport of complex bio-neutriceuticals
- Development of a “Graft versus Host Disease” model for personalised medicine/medical device evaluation
- Biofilm-removal efficacy testing on a 3D model of gum disease
- Anti-cancer drug screening in a 3D angiogenesis model of canine breast tumor
- Evaluation of a non-invasive tumor detection method using a human skin melanoma model
- Validation of an iPSC based Blood-Brain Barrier model for penetration and neurotoxicity
